Giant syringocystadenocarcinoma papilliferum with conjunctival recurrence: Possible Schimmelpenning syndrome with postzygotic <scp>G13R HRAS</scp> and <scp>K601N BRAF</scp> signature
Aurore Dupont(Bordeaux Population Health), L. Dousset(Centre Hospitalier Universitaire de Bordeaux), L. Dequidt(Bordeaux Population Health), Alain Taı̈eb(Hôpital Saint-André), Fanny Morice‐Picard(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), A. Pacaud(Hôpital Saint-André), Marie‐Laure Jullié(Centre Hospitalier Universitaire de Bordeaux), Charline Caumont(Inserm), Rémi Vergara(Université de Bordeaux), Valentine Saunier(Centre Hospitalier Universitaire de Bordeaux)
Cited by 4
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k